Drug Trial Radar · NCT02562235
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Actual
Start
Oct 29, 2015
Primary completion
Mar 7, 2020
Study completion May 15, 2028
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Sep 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.
Conditions
- Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)Drug
For children with body-weight \<50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Any Treatment-emergent Adverse EventsTime frame: From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.
- Change in Heart Rate From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Blood Pressure From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Respiratory Rate From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Number of Subjects With Transitions From Baseline in Bone Age Compared to Chronological AgeTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Hematology Parameters (Platelets) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Hematology Parameters (Lymphocytes/Leucocytes Ratio) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Hematology Parameter (Neutrophils/Leucocytes Ratio) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (Alanine Aminotransferase) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (Aspartate Aminotransferase) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (Sodium) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (Blood Urea Nitrogen) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (eGFR) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (Urea) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Change in Clinical Chemistry (Gamma Glutamyl Transferase) From BaselineTime frame: Baseline and Week 24 (plus/minus 5 days)
- Plasma Concentration of Riociguat at Week 0Time frame: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
- Plasma Concentration of Riociguat at Week 4Time frame: Week 4 (pre-dose)
- Plasma Concentration of Riociguat at Week 8Time frame: Week 8 (pre-dose)
- Plasma Concentration of BAY60-4552 at Week 0Time frame: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
- Plasma Concentration of BAY60-4552 at Week 4Time frame: Week 4 (pre-dose)
- Plasma Concentration of BAY60-4552 at Week 8Time frame: Week 8 (pre-dose)
Locations
16 sites in 9 countries. Site status is shown where the registry gives one.
Clínica Imbanaco S.A.S
Cali, Valle del Cauca Department, Colombia
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Ulm
Ulm, Baden-Wurttemberg, Germany
Deutsches Herzzentrum der Charité (DHZC)
Berlin, State of Berlin, Germany
Gottsegen Gyorgy Orszagos Kardiovaszkularis Intezet
Budapest, Budapest, Hungary
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, Csongrád-Csanád, Hungary
Azienda Ospedale-Università di Padova - UOC Cardiologia Pediatrica
Padova, Veneto, Italy
Aichi Children's Health and Medical Center
Ōbu, Aichi-ken, Japan
The University of Osaka Hospital
Suita, Osaka, Japan
National Cerebral and Cardiovascular Center
Suita, Osaka, Japan
Keio University Hospital
Shinjuku-ku, Tokyo, Japan
Instituto Nacional de Cardiología "Ignacio Chávez"
México D.F., Mexico City, Mexico
Operadora de Hospitales Angeles S. A. de C. V.
Huixquilucan, State of Mexico, Mexico
Wojewodzki Szpital Specjalistyczny - Wroclaw
Wroclaw, Poland
Veterans General Hospital
Kaohsiung City, Kaohsiung, Taiwan
Hacettepe Universitesi Tip Fakultesi
Ankara, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.